Predictive Biosciences, founded in 2006 and headquartered in Lexington, Massachusetts, is an early stage developer of intervention diagnostic assays for oncology management. The company offers biomarkers and proteomics-based assay technologies that detect urinary biomarkers associated with cancer development and progression. Their products include the Triage Monitoring Assay for delaying invasive diagnostic procedures, the Interval Monitoring Assay for surveillance and detection of cancer between follow-ups, and the Stratification Assay to support physicians' decision-making in patient management.